Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The pathogenesis of Parkinson's disease: a new hypothesis.

Literature DB >> 13966498

The pathogenesis of Parkinson's disease: a new hypothesis.

A BARBEAU.

Abstract

Entities: Disease

Keywords: BRAIN; CATECHOLAMINES; PARALYSIS AGITANS

Mesh：

Substances：
Catecholamines

Year: 1962 PMID： 13966498 PMCID： PMC1849683

Source DB: PubMed Journal: Can Med Assoc J ISSN： 0008-4409 Impact factor: 8.262

× No keyword cloud information.

32 in total

1. Some biochemical aspects of extrapyramidal diseases.

Authors: A BARBEAU; T L SOURKES
Journal: Rev Can Biol Date: 1961-06

2. [Determination of urinary 5-hydroxyindolacetic acid in Parkinson's disease].

Authors: A BARBEAU; G JASMIN
Journal: Rev Can Biol Date: 1961-12

3. Formation and catabolism of histamine in brain tissue in vitro.

Authors: T WHITE
Journal: J Physiol Date: 1959-12 Impact factor: 5.182

4. gamma-Aminobutyric acid and factor I.

Authors: K A ELLIOTT
Journal: Rev Can Biol Date: 1958-09

5. Studies on the distribution of Factor I in mammalian brain.

Authors: E FLOREY; E FLOREY
Journal: J Physiol Date: 1958-12-04 Impact factor: 5.182

6. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists.

Authors: A CARLSSON; M LINDQVIST; T MAGNUSSON
Journal: Nature Date: 1957-11-30 Impact factor: 49.962

7. The experimental evaluation of antiparkinsonian compounds.

Authors: K R UNNA; V G VERNIER
Journal: Ann N Y Acad Sci Date: 1956-11-16 Impact factor: 5.691

8. The site of action of antiparkinson drugs.

Authors: F RINALDI; H E HIMWICH
Journal: Confin Neurol Date: 1955

9. A cerebral decarboxylase for 5-hydroxytryptophane in humans.

Authors: W SACKS
Journal: J Appl Physiol Date: 1961-11 Impact factor: 3.531

10. Functional grafts of the anterior pituitary gland.

Authors: G W HARRIS; D JACOBSOHN
Journal: Proc R Soc Lond B Biol Sci Date: 1952-02-28

66 in total

1. Effects of desipramine on neuronal responses to dopamine, noradrenaline, 5-hydroxytryptamine and acetylcholine in the caudate nucleus of the rat.

Authors: P Bevan; C M Bradshaw; E Szabadi
Journal: Br J Pharmacol Date: 1975-07 Impact factor: 8.739

2. The effect of intrastriatal application of directly and indirectly acting dopamine agonists and antagonists on the in vivo release of acetylcholine measured by brain microdialysis. The importance of the post-surgery interval.

Authors: P De Boer; G Damsma; Q Schram; J C Stoof; J Zaagsma; B H Westerink
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1992-02 Impact factor: 3.000

3. [THE EFFICACY OF L-DOPA IN PARKINSON PATIENTS WITH AND WITHOUT STEREOTACTIC BRAIN SURGERY].

Authors: W UMBACH; D BAUMANN
Journal: Arch Psychiatr Nervenkr Date: 1964-06-01

4. Biochemical mechanisms and management of choreiform movement disorders.

Authors: L de Silva
Journal: Drugs Date: 1977-10 Impact factor: 9.546

5. Lack of involvement of dopaminergic and GABA neurones in the inhbitory effect of harmaline on the activity of striatal cholinergic neurones in the rat.

Authors: F Javoy; C Euvrard; A Herbet; J Bockaert; A Enjalbert; Y Agid; J Glowinski
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1977-04 Impact factor: 3.000

6. Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease.

Authors: Zixiu Xiang; Analisa D Thompson; Carrie K Jones; Craig W Lindsley; P Jeffrey Conn
Journal: J Pharmacol Exp Ther Date: 2011-12-01 Impact factor: 4.030